Subacute toxicity of all-trans-retinoic acid loaded biodegradable microspheres in rats

被引:4
作者
Choi, Y
Lee, C
Park, K
Kim, SY
Kim, SH
Han, S
Kim, SH
Byun, Y
机构
[1] Kwangju Inst Sci & Technol, Dept Mat Sci & Engn, Kwangju 500712, South Korea
[2] Shin Poong Pharmaceut Co Ltd, Cent Res Inst, Kyonggi Do, South Korea
[3] Univ Ulsan, Coll Med, Dept Otolaryngol, Seoul, South Korea
[4] Sungkyunkwan Univ, Coll Med, Dept Clin Pathol, Seoul, South Korea
[5] Gwangju Jeonnam Small & Medium Business Adm, Gwangju, South Korea
关键词
all-traps-retinoic acid; PDLLA; microsphere; subacute toxicity;
D O I
10.1002/ddr.10283
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Biodegradable microspheres containing all-traps-retinoic acid (atRA) were prepared previously to enhance the clinical efficacy of atRA for chemoprevention. In this study, subacute toxicity of atRA in sustained release was evaluated after subcutaneous administration of 0, 25, 50, and 100 mg atRA/kg of atRA-loaded microspheres. After the subcutaneous injection of atRA-loaded microspheres, the atRA concentration in plasma was maintained in the range of 3.5-25 ng/ml for 2-3 weeks. When 100 mg atRA/kg was administered, the atRA concentration in plasma was maintained at levels greater than 10 ng/ml and severe toxic effects were observed. When the dose of 50 mg atRA/kg was administered, the plasma concentration of atRA was maintained below 10 ng/ml over 3 weeks and only mild signs of toxicity were observed. Therefore, it was concluded that the dosage of atRA-loaded microspheres should be less than 50 mg atRA/kg for chemopreventive applications against carcinogenesis. Considering recovery from intoxication, the optimum interval for repeated injection of the microspheres was suggested to be over 4 weeks. In addition, it was found that the atRA concentration in plasma should be controlled below 10 ng/ml to minimize toxic effects of atRA. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:326 / 332
页数:7
相关论文
共 27 条
[1]  
ACHKAR CC, 1994, DRUG METAB DISPOS, V22, P451
[2]   DETERMINATION OF ISOTRETINOIN OR ETRETINATE AND THEIR MAJOR METABOLITES IN HUMAN-BLOOD BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BUGGE, CJL ;
RODRIGUEZ, LC ;
VANE, FM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1985, 3 (03) :269-277
[3]   In vivo biocompatibility studies of poly(D,L-lactide)/poly(ethylene glycol)-poly(L-lactide) microspheres containing all-trans-retinoic acid [J].
Choi, Y ;
Kim, SY ;
Kim, SH ;
Park, TG ;
Moon, HT ;
Byun, Y .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2002, 13 (03) :301-322
[4]   Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres [J].
Choi, Y ;
Kim, SY ;
Kim, SH ;
Lee, KS ;
Kim, C ;
Byun, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 215 (1-2) :67-81
[5]  
CULLUM ME, 1985, J BIOL CHEM, V260, P590
[6]   THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA [J].
FRANKEL, SR ;
EARDLEY, A ;
LAUWERS, G ;
WEISS, M ;
WARRELL, RP .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (04) :292-296
[7]   ALL-TRANS-RETINOIC ACID FOR ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF THE NEW-YORK STUDY [J].
FRANKEL, SR ;
EARDLEY, A ;
HELLER, G ;
BERMAN, E ;
MILLER, WH ;
DMITROVSKY, E ;
WARRELL, RP .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (04) :278-286
[8]  
Giannini F, 1997, INT J CANCER, V70, P194
[9]   TRETINOIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND USE IN THE MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].
GILLIS, JC ;
GOA, KL .
DRUGS, 1995, 50 (05) :897-923
[10]   EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON SUBLETHAL RETINOIC ACID TOXICITY IN SWISS MICE [J].
HIXSON, EJ ;
HARRISON, SD .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (12) :1714-1716